Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459543) titled 'A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Untreated Melanoma
Unresectable Melanoma
Metastatic Melanoma
Intervention:
Drug: Nivolumab + Relatlimab
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: November 15, 2026
Target Sample Siz...